Fig. 3.

Analogs of 6G-318S have lower inhibitory activity but are intein-specific. (A) Chemical structure of 6G-318S analogs. (B) Inhibition of the split-GFP–Prp8i splicing by the 6G-318S analogs at 20 µM. (C) Dose-dependent inhibition of the GFP–Prp8i intein splicing by 6G-319S, which was in twofold serial dilutions with concentrations ranging from 100 µM to 0.78 µM. n = 3. (D) No inhibition of the trypsin and papain protease activities by intein inhibitors. Compound concentration for cisplatin, 6G-318S, and 6G-319S was set at 400 µM. Control inhibitor AP-2HCl was at 3.5 µM. n = 3.